^
    Apply
    Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer (NCT00710710)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    05/04/2022
    Initiation :
    08/01/2006
    Primary completion :
    10/14/2008
    Completion :
    10/14/2008
    CA 19-9
    |
    BI2536